Research
Molecular
Semaglutide has a higher pooled reporting odds ratio (ROR) for gastrointestinal adverse drug reactions (GADRs) compared to liraglutide (5.53 vs 3.95).
Clinicians should consider the higher gastrointestinal risk associated with semaglutide when prescribing.
StrongSupportsmedium confidence
semaglutide had a higher pooled ROR... compared with those of liraglutide (5.53, 95% CI 5.23– 5.85 vs 3.95, 95% CI 3.81– 4.10)
Why this rating
Based on the analysis of real-world data from a pharmacovigilance database.
Source
Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study
Yu Zhou et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 2022
other · n=6222Cited 15×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →